{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T07:23:40Z","timestamp":1793345020553,"version":"4.5.0"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T00:00:00Z","timestamp":1567468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s00259-019-04504-3","type":"journal-article","created":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T01:30:28Z","timestamp":1567474228000},"page":"123-135","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":137,"title":["First-in-human dosimetry of gastrin-releasing peptide receptor antagonist [177Lu]Lu-RM2: a radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6864-4513","authenticated-orcid":false,"given":"Jens","family":"Kurth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernd Joachim","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Schwarzenb\u00f6ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bergner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Hakenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Heuschkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,3]]},"reference":[{"issue":"4","key":"4504_CR1","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"key":"4504_CR2","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Interdisziplin\u00e4re Leitlinie der Qualit\u00e4t S3 zur Fr\u00fcherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Langversion 5.1, 2019, AWMF Registernummer: 043\/022OL. \nhttp:\/\/www.leitlinienprogramm-onkologie.de\/leitlinien\/prostatakarzinom\/\n\n. Accessed 15.07. 2019."},{"issue":"1","key":"4504_CR3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1002\/jmrs.227","volume":"64","author":"L Emmett","year":"2017","unstructured":"Emmett L, Willowson K, Violet J, Shin J, Blanksby A, Lee J. Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52\u201360.","journal-title":"J Med Radiat Sci"},{"issue":"1","key":"4504_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2967\/jnumed.116.183194","volume":"58","author":"K Rahbar","year":"2017","unstructured":"Rahbar K, Ahmadzadehfar H, Kratochwil C, Haberkorn U, Schafers M, Essler M, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58(1):85\u201390.","journal-title":"J Nucl Med"},{"issue":"6","key":"4504_CR5","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333.","journal-title":"Lancet Oncol"},{"key":"4504_CR6","unstructured":"ClinicalTrials.gov\n\n. Identifier NCT03511664, Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer (VISION). Bethesda: National Library of Medicine (US). 2000. [\nhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT03511664\n\n]. Accessed 01.03.2019."},{"issue":"5","key":"4504_CR7","first-page":"1152","volume":"59","author":"R Markwalder","year":"1999","unstructured":"Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res. 1999;59(5):1152\u20139.","journal-title":"Cancer Res"},{"issue":"4","key":"4504_CR8","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(SICI)1097-0045(20000301)42:4<295::AID-PROS7>3.0.CO;2-B","volume":"42","author":"B Sun","year":"2000","unstructured":"Sun B, Halmos G, Schally AV, Wang X, Martinez M. Presence of receptors for bombesin\/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers. Prostate. 2000;42(4):295\u2013303.","journal-title":"Prostate"},{"issue":"1","key":"4504_CR9","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00259-010-1596-9","volume":"38","author":"R Mansi","year":"2011","unstructured":"Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging. 2011;38(1):97\u2013107.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"19","key":"4504_CR10","doi-asserted-by":"publisher","first-page":"5434","DOI":"10.1158\/1078-0432.CCR-12-3490","volume":"19","author":"E K\u00e4hkonen","year":"2013","unstructured":"K\u00e4hkonen E, Jambor I, Kemppainen J, Lehtio K, Gronroos TJ, Kuisma A, et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013;19(19):5434\u201343.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"4504_CR11","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2967\/jnumed.115.168393","volume":"57","author":"R Minamimoto","year":"2016","unstructured":"Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, et al. Pilot comparison of 68Ga-RM2 PET and 68Ga-PSMA-11 PET in patients with biochemically recurrent prostate cancer. J Nucl Med. 2016;57(4):557\u201362.","journal-title":"J Nucl Med"},{"issue":"2","key":"4504_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.euo.2018.08.011","volume":"2","author":"KA Touijer","year":"2019","unstructured":"Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, et al. Prospective study of the radiolabeled GRPR antagonist BAY86-7548 for positron emission tomography\/computed tomography imaging of newly diagnosed prostate cancer. Eur Urol Oncol. 2019;2(2):166\u201373.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"4504_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2967\/jnumed.117.197624","volume":"59","author":"R Minamimoto","year":"2018","unstructured":"Minamimoto R, Sonni I, Hancock S, Vasanawala S, Loening A, Gambhir SS, et al. Prospective evaluation of (68)Ga-RM2 PET\/MRI in patients with biochemical recurrence of prostate cancer and negative findings on conventional imaging. J Nucl Med. 2018;59(5):803\u20138.","journal-title":"J Nucl Med"},{"issue":"6","key":"4504_CR14","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2967\/jnumed.112.114082","volume":"54","author":"A Roivainen","year":"2013","unstructured":"Roivainen A, Kahkonen E, Luoto P, Borkowski S, Hofmann B, Jambor I, et al. Plasma pharmacokinetics, whole-body distribution, metabolism, and radiation dosimetry of 68Ga bombesin antagonist BAY 86-7548 in healthy men. J Nucl Med. 2013;54(6):867\u201372.","journal-title":"J Nucl Med"},{"issue":"1","key":"4504_CR15","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13550-018-0462-9","volume":"8","author":"S Gnesin","year":"2018","unstructured":"Gnesin S, Cicone F, Mitsakis P, Van der Gucht A, Baechler S, Miralbell R, et al. First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist (68)Ga-NODAGA-MJ9. EJNMMI Res. 2018;8(1):108.","journal-title":"EJNMMI Res"},{"issue":"1","key":"4504_CR16","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2967\/jnumed.115.165316","volume":"57","author":"J Zhang","year":"2016","unstructured":"Zhang J, Li D, Lang L, Zhu Z, Wang L, Wu P, et al. 68Ga-NOTA-aca-BBN(7-14) PET\/CT in healthy volunteers and glioma patients. J Nucl Med. 2016;57(1):9\u201314.","journal-title":"J Nucl Med"},{"issue":"6","key":"4504_CR17","doi-asserted-by":"publisher","first-page":"922","DOI":"10.2967\/jnumed.117.198929","volume":"59","author":"J Zhang","year":"2018","unstructured":"Zhang J, Niu G, Fan X, Lang L, Hou G, Chen L, et al. PET using a GRPR antagonist (68)Ga-RM26 in healthy volunteers and prostate cancer patients. J Nucl Med. 2018;59(6):922\u20138.","journal-title":"J Nucl Med"},{"issue":"4","key":"4504_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nrurol.2013.42","volume":"10","author":"R Mansi","year":"2013","unstructured":"Mansi R, Fleischmann A, Macke HR, Reubi JC. Targeting GRPR in urological cancers--from basic research to clinical application. Nat Rev Urol. 2013;10(4):235\u201344.","journal-title":"Nat Rev Urol"},{"issue":"2","key":"4504_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2967\/jnumed.116.176636","volume":"58","author":"SU Dalm","year":"2017","unstructured":"Dalm SU, Bakker IL, de Blois E, Doeswijk GN, Konijnenberg MW, Orlandi F, et al. 68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for theranostic use in oncology. J Nucl Med. 2017;58(2):293\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"4504_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.107.07108","volume":"60","author":"RT Jensen","year":"2008","unstructured":"Jensen RT, Battey JF, Spindel ER, Benya RV. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol Rev. 2008;60(1):1\u201342.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"4504_CR21","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2967\/jnumed.112.107524","volume":"54","author":"M Sandstrom","year":"2013","unstructured":"Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing 177Lu-DOTA-octreotate treatment. J Nucl Med. 2013;54(1):33\u201341.","journal-title":"J Nucl Med"},{"issue":"3","key":"4504_CR22","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1089\/cbr.2006.325","volume":"22","author":"C Wehrmann","year":"2007","unstructured":"Wehrmann C, Senftleben S, Zachert C, Muller D, Baum RP. Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC. Cancer Biother Radiopharm. 2007;22(3):406\u201316.","journal-title":"Cancer Biother Radiopharm"},{"issue":"10","key":"4504_CR23","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1007\/s00259-003-1255-5","volume":"30","author":"D Wild","year":"2003","unstructured":"Wild D, Schmitt JS, Ginj M, Macke HR, Bernard BF, Krenning E, et al. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals. Eur J Nucl Med Mol Imaging. 2003;30(10):1338\u201347.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"4504_CR24","doi-asserted-by":"publisher","first-page":"914","DOI":"10.2967\/jnumed.114.147413","volume":"56","author":"M Benesova","year":"2015","unstructured":"Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer. J Nucl Med. 2015;56(6):914\u201320.","journal-title":"J Nucl Med"},{"issue":"1","key":"4504_CR25","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00259-015-3174-7","volume":"43","author":"A Delker","year":"2016","unstructured":"Delker A, Fendler WP, Kratochwil C, Brunegraf A, Gosewisch A, Gildehaus FJ, et al. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(1):42\u201351.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"4504_CR26","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1007\/s00259-015-3125-3","volume":"42","author":"L Kabasakal","year":"2015","unstructured":"Kabasakal L, AbuQbeitah M, Aygun A, Yeyin N, Ocak M, Demirci E, et al. Pre-therapeutic dosimetry of normal organs and tissues of (177)Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(13):1976\u201383.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4504_CR27","unstructured":"World Medical Association (WMA) Declaration of Helsinki \u2013 Ethical Principles For Medical Research Involving Human Subjects. \nhttps:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/\n\n. Accessed 03.03. 2019."},{"issue":"10","key":"4504_CR28","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1118\/1.597423","volume":"22","author":"DJ Macey","year":"1995","unstructured":"Macey DJ, Grant EJ, Bayouth JE, Giap HB, Danna SJ, Sirisriro R, et al. Improved conjugate view quantitation of I-131 by subtraction of scatter and septal penetration events with a triple energy window method. Med Phys. 1995;22(10):1637\u201343.","journal-title":"Med Phys"},{"issue":"1","key":"4504_CR29","doi-asserted-by":"publisher","first-page":"151","DOI":"10.2967\/jnumed.115.159012","volume":"57","author":"M Ljungberg","year":"2016","unstructured":"Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjogreen-Gleisner K, et al. MIRD pamphlet no. 26: joint EANM\/MIRD guidelines for quantitative 177Lu SPECT applied for dosimetry of radiopharmaceutical therapy. J Nucl Med. 2016;57(1):151\u201362.","journal-title":"J Nucl Med"},{"issue":"7","key":"4504_CR30","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.2967\/jnumed.107.050203","volume":"49","author":"P Zanzonico","year":"2008","unstructured":"Zanzonico P. Routine quality control of clinical nuclear medicine instrumentation: a brief review. J Nucl Med. 2008;49(7):1114\u201331.","journal-title":"J Nucl Med"},{"key":"4504_CR31","volume-title":"Fundamentals for nuclear medicine dosimetry","author":"MG Stabin","year":"2008","unstructured":"Stabin MG. Fundamentals for nuclear medicine dosimetry. New York: Springer; 2008."},{"issue":"2","key":"4504_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cam.2004.02.013","volume":"172","author":"C Kanzow","year":"2004","unstructured":"Kanzow C, Yamashita N, Fukushima T. Levenberg-Marquardt methods with strong local convergence properties for solving nonlinear equations with convex constraints. J Comput Appl Math. 2004;172(2):375\u201397.","journal-title":"J Comput Appl Math"},{"key":"4504_CR33","unstructured":"Lourakis M. levmar: Levenberg-Marquardt nonlinear least squares algorithms in C\/C++. 2004. \nhttp:\/\/www.ics.forth.gr\/~lourakis\/levmar\/\n\n. Accessed 22.03. 2019."},{"issue":"5","key":"4504_CR34","first-page":"supplement 1 58","volume":"53","author":"MG Stabin","year":"2012","unstructured":"Stabin MG, Farmer A. OLINDA\/EXM 2.0: The new generation dosimetry modeling code [abstract]. J Nucl Med. 2012;53(5):supplement 1 585.","journal-title":"J Nucl Med"},{"issue":"11","key":"4504_CR35","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.2967\/jnumed.112.106138","volume":"53","author":"MG Stabin","year":"2012","unstructured":"Stabin MG, Xu XG, Emmons MA, Segars WP, Shi C, Fernald MJ. RADAR reference adult, pediatric, and pregnant female phantom series for internal and external dosimetry. J Nucl Med. 2012;53(11):1807\u201313.","journal-title":"J Nucl Med"},{"issue":"2","key":"4504_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.icrp.2009.07.001","volume":"39","author":"HG Menzel","year":"2009","unstructured":"Menzel HG, Clement C, DeLuca P. ICRP Publication 110. Realistic reference phantoms: an ICRP\/ICRU joint effort. A report of adult reference computational phantoms. Ann ICRP. 2009;39(2):1\u2013164.","journal-title":"Ann ICRP"},{"issue":"1","key":"4504_CR37","first-page":"149","volume":"41","author":"MG Stabin","year":"2000","unstructured":"Stabin MG, Konijnenberg MW. Re-evaluation of absorbed fractions for photons and electrons in spheres of various sizes. J Nucl Med. 2000;41(1):149\u201360.","journal-title":"J Nucl Med"},{"issue":"1","key":"4504_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1118\/1.597057","volume":"20","author":"A Kojima","year":"1993","unstructured":"Kojima A, Takaki Y, Matsumoto M, Tomiguchi S, Hara M, Shimomura O, et al. A preliminary phantom study on a proposed model for quantification of renal planar scintigraphy. Med Phys. 1993;20(1):33\u20137.","journal-title":"Med Phys"},{"issue":"2","key":"4504_CR39","first-page":"37S","volume":"40","author":"JA Siegel","year":"1999","unstructured":"Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S\u201361S.","journal-title":"J Nucl Med"},{"issue":"6","key":"4504_CR40","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1007\/s00259-010-1422-4","volume":"37","author":"C Hindorf","year":"2010","unstructured":"Hindorf C, Glatting G, Chiesa C, Linden O, Flux G. EANM Dosimetry Committee guidelines for bone marrow and whole-body dosimetry. Eur J Nucl Med Mol Imaging. 2010;37(6):1238\u201350.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"17","key":"4504_CR41","doi-asserted-by":"publisher","first-page":"5231","DOI":"10.1088\/0031-9155\/52\/17\/009","volume":"52","author":"AC Traino","year":"2007","unstructured":"Traino AC, Ferrari M, Cremonesi M, Stabin MG. Influence of total-body mass on the scaling of S-factors for patient-specific, blood-based red-marrow dosimetry. Phys Med Biol. 2007;52(17):5231\u201348.","journal-title":"Phys Med Biol"},{"issue":"1","key":"4504_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13550-018-0427-z","volume":"8","author":"A Gosewisch","year":"2018","unstructured":"Gosewisch A, Delker A, Tattenberg S, Ilhan H, Todica A, Brosch J, et al. Patient-specific image-based bone marrow dosimetry in Lu-177-[DOTA(0),Tyr(3)]-octreotate and Lu-177-DKFZ-PSMA-617 therapy: investigation of a new hybrid image approach. EJNMMI Res. 2018;8(1):76.","journal-title":"EJNMMI Res"},{"issue":"1","key":"4504_CR43","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13550-018-0386-4","volume":"8","author":"J Kurth","year":"2018","unstructured":"Kurth J, Krause BJ, Schwarzenbock SM, Stegger L, Schafers M, Rahbar K. External radiation exposure, excretion, and effective half-life in (177)Lu-PSMA-targeted therapies. EJNMMI Res. 2018;8(1):32.","journal-title":"EJNMMI Res"},{"issue":"1","key":"4504_CR44","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109\u201322.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 Suppl","key":"4504_CR45","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.ijrobp.2009.09.040","volume":"76","author":"SM Bentzen","year":"2010","unstructured":"Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S3\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4504_CR46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1748-717X-8-247","volume":"8","author":"S Bresciani","year":"2013","unstructured":"Bresciani S, Garibaldi E, Cattari G, Maggio A, Di Dia A, Delmastro E, et al. Dose to organs at risk in the upper abdomen in patients treated with extended fields by helical tomotherapy: a dosimetric and clinical preliminary study. Radiat Oncol. 2013;8:247.","journal-title":"Radiat Oncol"},{"issue":"1","key":"4504_CR47","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s13014-018-1189-5","volume":"13","author":"C Gemici","year":"2018","unstructured":"Gemici C, Yaprak G, Ozdemir S, Baysal T, Seseogullari OO, Ozyurt H. Volumetric decrease of pancreas after abdominal irradiation, it is time to consider pancreas as an organ at risk for radiotherapy planning. Radiat Oncol. 2018;13(1):238.","journal-title":"Radiat Oncol"},{"issue":"3","key":"4504_CR48","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.radonc.2015.11.033","volume":"118","author":"J Wydmanski","year":"2016","unstructured":"Wydmanski J, Polanowski P, Tukiendorf A, Maslyk B. Radiation-induced injury of the exocrine pancreas after chemoradiotherapy for gastric cancer. Radiother Oncol. 2016;118(3):535\u20139.","journal-title":"Radiother Oncol"},{"issue":"7","key":"4504_CR49","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1007\/s00259-009-1072-6","volume":"36","author":"F Forrer","year":"2009","unstructured":"Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging. 2009;36(7):1138\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"4504_CR50","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1200\/JCO.2007.15.2553","volume":"26","author":"DJ Kwekkeboom","year":"2008","unstructured":"Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26(13):2124\u201330.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4504_CR51","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42(1):5\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"4504_CR52","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1667\/RR3021","volume":"159","author":"CN Coleman","year":"2003","unstructured":"Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, et al. Molecular and cellular biology of moderate-dose (1\u201310 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17\u201318, 2001. Radiat Res. 2003;159(6):812\u201334.","journal-title":"Radiat Res"},{"issue":"1","key":"4504_CR53","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/MNM.0000000000000606","volume":"38","author":"MP Yadav","year":"2017","unstructured":"Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer. Nucl Med Commun. 2017;38(1):91\u20138.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"4504_CR54","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in peptide radionuclide receptor therapy: a review. J Nucl Med. 2006;47(9):1467\u201375.","journal-title":"J Nucl Med"},{"issue":"Suppl 1","key":"4504_CR55","first-page":"99S","volume":"46","author":"R Barone","year":"2005","unstructured":"Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med. 2005;46(Suppl 1):99S\u2013106S.","journal-title":"J Nucl Med"},{"issue":"6","key":"4504_CR56","first-page":"1141","volume":"41","author":"S Van Binnebeek","year":"2014","unstructured":"Van Binnebeek S, Baete K, Vanbilloen B, Terwinghe C, Koole M, Mottaghy FM, et al. Individualized dosimetry-based activity reduction of (9)(0)Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2014;41(6):1141\u201357.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"4504_CR57","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1007\/s00259-017-3678-4","volume":"44","author":"A Sundlov","year":"2017","unstructured":"Sundlov A, Sjogreen-Gleisner K, Svensson J, Ljungberg M, Olsson T, Bernhardt P, et al. Individualised (177)Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur J Nucl Med Mol Imaging. 2017;44(9):1480\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"4504_CR58","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s11307-016-0942-0","volume":"18","author":"M Hohberg","year":"2016","unstructured":"Hohberg M, Eschner W, Schmidt M, Dietlein M, Kobe C, Fischer T, et al. Lacrimal glands may represent organs at risk for radionuclide therapy of prostate cancer with [(177)Lu]DKFZ-PSMA-617. Mol Imaging Biol. 2016;18(3):437\u201345.","journal-title":"Mol Imaging Biol"},{"issue":"4","key":"4504_CR59","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.zemedi.2011.05.001","volume":"21","author":"J Fitschen","year":"2011","unstructured":"Fitschen J, Knoop BO, Behrendt R, Knapp WH, Geworski L. External radiation exposure and effective half-life in Lu-177-Dota-Tate therapy. Z Med Phys. 2011;21(4):266\u201373.","journal-title":"Z Med Phys"},{"issue":"5","key":"4504_CR60","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11307-015-0839-3","volume":"17","author":"A Delker","year":"2015","unstructured":"Delker A, Ilhan H, Zach C, Brosch J, Gildehaus FJ, Lehner S, et al. The influence of early measurements onto the estimated kidney dose in [(177)Lu][DOTA(0),Tyr(3)]octreotate peptide receptor radiotherapy of neuroendocrine tumors. Mol Imaging Biol. 2015;17(5):726\u201334.","journal-title":"Mol Imaging Biol"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04504-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04504-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T19:16:30Z","timestamp":1598987790000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04504-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["4504"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04504-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]},"assertion":[{"value":"13 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The need for a formal review of this retrospective study was waived by the Ethical Committee of the University of Rostock (file no. A 2018-0240).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent to undergo therapy with subsequent follow-up was obtained from all patients included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}